Immune Therapeutics is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of its novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. Company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK).
TypePublic
HQOrlando, US
Founded2012
Size (employees)10 (est)
Websiteimmunetherapeutics.com
Immune Therapeutics was founded in 2012 and is headquartered in Orlando, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Immune Therapeutics Office Locations

Immune Therapeutics has an office in Orlando
Orlando, US (HQ)
607 37 N Orange Ave
Show all (1)
Report incorrect company information

Immune Therapeutics Financials and Metrics

Immune Therapeutics Revenue

Immune Therapeutics's revenue was reported to be $3.46 k in FY, 2016 which is a 78.6% decrease from the previous period.
USD

Revenue (Q2, 2018)

65 k

Gross profit (Q2, 2018)

31.8 k

Gross profit margin (Q2, 2018), %

49%

Net income (Q2, 2018)

(5.1 m)

EBIT (Q2, 2018)

(2.6 m)

Market capitalization (19-Sep-2018)

7.9 m
Immune Therapeutics's current market capitalization is $7.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

16.2 k3.5 k

Revenue growth, %

(79%)

General and administrative expense

71.1 m4.1 m2.7 m3.9 m

Operating expense total

71.1 m4.1 m2.7 m3.9 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

2.1 k5.6 k5 k3.5 k65 k65 k

Cost of goods sold

33.2 k33.2 k

Gross profit

31.8 k31.8 k

Gross profit Margin, %

49%49%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

406.6 k192 k23.1 k74.4 k

Accounts Receivable

16.2 k

Current Assets

622.5 k222 k39.3 k74.4 k

Total Assets

19.2 m6.1 m41.2 k76.4 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

58.7 k58.6 k30.9 k22.4 k153.9 k132.8 k64.3 k22.2 k98.1 k22.6 k30.4 k

Accounts Receivable

2.1 k7.7 k12.7 k19.7 k2.7 k

Inventories

214.3 k158.6 k158.6 k

Current Assets

93.7 k108.3 k62.9 k60.1 k211.9 k153.4 k78.2 k22.2 k98.1 k236.9 k189 k158.6 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(106.1 m)(49.9 m)(16.9 m)(19.8 m)

Depreciation and Amortization

1.2 k2.5 k2.6 k1.6 k

Inventories

246.3 k40 k

Accounts Payable

553.2 k1.8 m900.5 k541 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(11.2 m)(2.9 m)(2.6 m)(6.6 m)(2.7 m)(731.9 k)(5.1 m)

Depreciation and Amortization

434 867

Inventories

19.5 k19.5 k

Accounts Payable

1.6 m1.8 m1.9 m1.9 m1.9 m1.9 m1.5 m1.5 m1.7 m78.2 k521.8 k
Show all financial metrics
Report incorrect company information

Immune Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Immune Therapeutics News and Updates

Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors

ORLANDO, Fla., Sept. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and infla…

Renown HIV specialist Dr. Gary Blick Joins Immune Therapeutics Advisory Board

ORLANDO, Fla., Aug. 23, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune Therapeutics", "IMUN" or the "Company"), a late stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory…
Report incorrect company information

Immune Therapeutics Company Life and Culture

Report incorrect company information